Outcomes after switching from 144 weeks of blinded DTG/ABC/3TC or DTG+F/TAF to 96 weeks of open-label B/F/TAF

被引：0
|
作者：
Orkin, C. [1 ]
Antinori, A. [2 ]
Rockstroh, J. [3 ]
Guillen, S. Moreno [4 ]
Martorell, C. [5 ]
Molina, J. [6 ]
Lazzarin, A. [7 ]
Maggiolo, F. [8 ]
Yazdanpanah, Y. [9 ]
Andreatta, K. [10 ]
Huang, H. [11 ]
Hindman, J. [12 ]
Martin, H. [12 ]
Baeten, J. [12 ]
Pozniak, A. [13 ]
机构：
[1] Queen Mary Univ London, HIV Med, London, England
[2] Natl Inst Infect Dis, Lazzaro Spallanzani IRCCS, Rome, Italy
[3] Univ Hosp Bonn, Med Klin & Poliklin I, Bonn, Germany
[4] Hosp Ramon & Cajal, Dept Infect Dis, Madrid, Spain
[5] Res Inst, Infect Dis, Springfield, MA USA
[6] Univ Paris, Infect Dis, Paris, France
[7] San Raffaele Hosp Milan, Lazzaro Spallanzani IRCCS, Milan, Italy
[8] Azienda Osped Papa Giovanni XXIII, Infect Dis, Bergamo, Italy
[9] AP HP Hop Bichat, Infect Dis, Paris, France
[10] Gilead Sci, Clin Virol, Foster City, CA USA
[11] Gilead Sci, Biostat Virol, Foster City, CA USA
[12] Gilead Sci, Clin Dev, Foster City, CA USA
[13] Chelsea & Westminster Hosp, Clin Res, London, England
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2022年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P088
引用
收藏
页码：88 / 89
页数：2
相关论文
共 45 条
  • [31] Durable efficacy of switching from a three-/four-drug tenofovir alafenamide (TAF)-based regimen to the two-drug regimen dolutegravir/lamivudine (DTG/3TC) in the TANGO study through week 196
    De Wit, S.
    Bonnet, F.
    Osiyemi, O.
    Bisshop, F.
    Olalla, J.
    Routy, J.
    Wyen, C.
    Moodley, R.
    Pappa, K.
    Wang, R.
    Oyee, J.
    Saggu, P.
    Letang, E.
    Wynne, B.
    Jones, B.
    Smith, K.
    Ait-Khaled, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 12 - 13
  • [32] Correction to: Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study
    Chun-Yuan Lee
    Chen-Hsiang Lee
    Hung-Jen Tang
    Hung-Chin Tsai
    Chen-Hsun Yang
    Yi-Pei Lin
    Sheng-Fan Wang
    Po-Liang Lu
    Infectious Diseases and Therapy, 2023, 12 : 863 - 869
  • [33] PAIRED-PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a sub-analysis of people with HIV (PWH) switching from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in the United States
    Slim, Jihad
    Brogan, Andrew P.
    Harper, Gavin
    Mycock, Katie
    McMillan, Abigail
    Merrill, Deanna
    Verdier, Gustavo
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 111 - 112
  • [34] Switching from a 3-drug tenofovir alafenamide (TAF)-based regimen (TBR) to a 2-drug dolutegravir/lamivudine (2DR, DTG/3TC FDC) was not associated with a higher frequency of intermittent viremia in suppressed patients in the TANGO study
    Wang, R.
    Horton, J.
    Wright, J.
    Razeek, R.
    Ait-Khaled, M.
    Nascimento, M. C.
    Tenorio, A. R.
    Underwood, M.
    HIV MEDICINE, 2019, 20 : 95 - 95
  • [35] Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study (vol 12, pg 843, 2023)
    Lee, Chun-Yuan
    Lee, Chen-Hsiang
    Tang, Hung-Jen
    Tsai, Hung-Chin
    Yang, Chen-Hsun
    Lin, Yi-Pei
    Wang, Sheng-Fan
    Lu, Po-Liang
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (03) : 863 - 869
  • [36] Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial
    Kityo, Cissy
    Hagins, Debbie
    Koenig, Ellen
    Avihingsanon, Anchalee
    Chetchotisakd, Ploenchan
    Supparatpinyo, Khuanchai
    Gankina, Natalya
    Pokrovsky, Vadim
    Voronin, Evgeny
    Stephens, Jeffrey L.
    DeJesus, Edwin
    Wang, Hui
    Acosta, Rima K.
    Cao, Huyen
    Quirk, Erin
    Martin, Hal
    Makadzange, Tariro
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 82 (03) : 321 - 328
  • [37] Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance- a phase IV randomised, open-label study (PIBIK study)
    Iwuji, Collins
    Waters, Laura
    Milinkovic, Ana
    Orkin, Chloe
    Fox, Julie
    Post, Frank
    Perry, Nicky
    Bruce, Chloe
    Dailey, Natalie
    To, Ye
    Bremner, Stephen
    Churchill, Duncan
    Geretti, Anna Maria
    VIROLOGY JOURNAL, 2025, 22 (01)
  • [38] No confirmed virological failures (CVF) for 144 weeks when switching 2-/3-/4-drug ART to DTG/3TC in heavily treatment-experienced PLWHA with prior M184V/I and virological failures (VF) in the prospective SOLAR-3D study
    Blick, G.
    Cerreta-Dial, E.
    Mancini, G.
    Cosenza, A.
    Fang, L.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 104 - 104
  • [39] Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Spelman, Lynda
    Eyerich, Kilian
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 14 - 14
  • [40] Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48-144) of the BE RADIANT phase 3b trial
    Strober, Bruce
    Puig, Luis
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    Wang, Maggie
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Wiegratz, Susanne
    Paul, Carle
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB21 - AB21
12345